Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-TargetLaurent Peyrin‐Biroulet, Marla C. Dubinsky, Brian G. Feagan et al.|The American Journal of Gastroenterology|2015Cited by 1.8k
Risk for colorectal cancer in ulcerative colitis: Changes, causes and management strategiesPéter L. Lakatos|World Journal of Gastroenterology|2008Cited by 445
Global evolution of inflammatory bowel disease across epidemiologic stagesLindsay Hracs, Shinji Okabayashi, Joseph W. Windsor et al.|Nature|2025Cited by 294
Estrogen receptor alpha XbaI polymorphism, toxic adenoma, and thyroid hormone-stimulated bone lossI Takács, Péter L. Lakatos, Éva Bajnok et al.|UCL Discovery (University College London)|2004Cited by 0
226 THE PROGNOSTIC SIGNIFICANCE OF PREOPERATIVE SERUM LEVELS OF EXTRACELLULAR MATRIX PROTEIN 1 IN PATIENTS WITH HEPATOCELLULAR CARCINOMAE Horváth, Jiaqi Huang, Péter L. Lakatos et al.|Unknown|2011Cited by 0